What drug class does Quviviq (daridorexant) belong to?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Quviviq Drug Classification

Quviviq (daridorexant) is an orexin receptor antagonist, specifically a dual orexin receptor antagonist (DORA), classified as a Schedule IV controlled substance. 1

Mechanism of Action

Daridorexant works by blocking both OX1R and OX2R orexin receptors (Ki = 0.47 and 0.93 nM, respectively). The orexin neuropeptide signaling system promotes wakefulness, and by antagonizing these receptors, daridorexant suppresses the wake drive, thereby facilitating sleep 1. This represents a fundamentally different mechanism compared to traditional sedative-hypnotics like benzodiazepines or Z-drugs, which enhance GABA activity.

Regulatory Classification

  • DEA Schedule: Schedule IV controlled substance 1
  • FDA Indication: Treatment of insomnia disorder characterized by difficulty falling asleep and/or maintaining sleep 1
  • Available doses: 25 mg and 50 mg oral tablets 1

Clinical Context

Daridorexant is one of the newer orexin receptor antagonists approved since the 2017 AASM guidelines on pharmacological treatment of chronic insomnia 2. It joins other dual orexin receptor antagonists like suvorexant and lemborexant in this drug class 2. The medication has been studied for up to 12 months in clinical trials with 1232 subjects, showing no reports indicative of abuse liability during that period 1.

Abuse Potential

While classified as Schedule IV, daridorexant demonstrated lower "drug liking" ratings than zolpidem and suvorexant at the therapeutic 50 mg dose in recreational drug users. However, at supratherapeutic doses (100-150 mg), it showed similar abuse potential to these comparators 1. The drug does not produce physical dependence or withdrawal symptoms upon discontinuation 1.

References

Guideline

combination treatment for chronic insomnia disorder in adults: an american academy of sleep medicine clinical practice guideline.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.